| Name | Title | Contact Details |
|---|
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.
Elite Diagnostics is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aspen Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OmniAb is a leading edge antibody discovery company that provides access to diverse antibody repertoires and high throughput screening technologies. They specialize in therapeutic antibody discovery using chickens as immunization hosts, which allows fo...
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.